Johnson County Clin-Trials (United States)

Recent papers from Johnson County Clin-Trials (United States)

1. Safety and Immunogenicity of the Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults: Results from a Phase 2, Randomized, Controlled, Dose-Finding Trial with Long-Term Extension Follow-Up Through Month 48Vaccines · 2026
2. The Dorsal Forearm as a Novel Target for Intramuscular Injections: Clinical Pharmacokinetic Results With NaloxoneClinical and Translational Science · 2025
3. Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical studyFrontiers in Immunology · 2025
4. An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titersSHILAP Revista de lepidopterología · 2025
5. Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescentsHuman Vaccines & Immunotherapeutics · 2025
6. Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study2024
7. A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTInpj Vaccines · 2024
8. Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical TrialThe Journal of Infectious Diseases · 2024
9. Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a StudyOpen Forum Infectious Diseases · 2023
10. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in AdultsThe Journal of Infectious Diseases · 2022
11. Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in AdultsVaccines · 2021
12. Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant WomenThe Journal of Infectious Diseases · 2021
13. A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus VaccineAnnals of Internal Medicine · 2021
14. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trialVaccine · 2020
15. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trialHuman Vaccines & Immunotherapeutics · 2020
16. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adultsVaccine · 2019
17. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialnpj Vaccines · 2018
18. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 TrialsThe Journal of Infectious Diseases · 2018
19. Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion ProteinsOpen Forum Infectious Diseases · 2016
20. Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging StudyThe Journal of Infectious Diseases · 2014